期刊
TRANSPLANT INTERNATIONAL
卷 25, 期 5, 页码 e62-e66出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1432-2277.2012.01462.x
关键词
Focal segmental glomerulosclerosis; Renal transplantation; Recurrence; Rituximab
资金
- Association pour l'Utilisation du Rein Artificiel (AURA)
Preventive treatment of focal and segmental glomerusclerosis (FSGS) allograft recurrence in high risk recipients having a prior history of graft loss caused by FSGS recurrence is still a challenging question. We retrospectively identified four patients who underwent a second renal transplantation because of recurrent FSGS and who received Rituximab therapy as a prophylactic treatment. Loss of their first allograft was directly related to an early (<3 months) recurrence of FSGS that was either resistant to plasmapheresis therapy in two cases or had escaped to this therapeutic management in the two others. After the second renal transplantation, all patients were free of FSGS recurrence during follow-ups that were between 12 and 54 months long. These preliminary results demonstrate for the first time that Rituximab therapy may constitute an attractive prophylactic option for patients being considered for a second renal transplantation because of recurrent FSGS in their first graft.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据